- Home
- VBF vs SPRO Comparison
VBF vs SPRO Comparison
Compare VBF & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VBF | SPRO |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.7M | 156.3M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VBF | SPRO |
|---|---|---|
| Price | $14.98 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.5K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $14.68 | $1.80 |
| 52 Week High | $15.98 | $3.09 |
Technical Indicators
Market Signals| Indicator | VBF | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 38.98 |
| Support Level | $14.91 | $2.19 |
| Resistance Level | $15.21 | $2.47 |
| Average True Range (ATR) | 0.16 | 0.26 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 39.02 | 29.54 |
Price Performance
Historical ComparisonAbout VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.